Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | CHD1L | Q86WJ1 | 1/20 | 0.57 |
| ▸ | PARP9 | Q8IXQ6 | 1/20 | 0.57 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FABP4 | P15090 | 9/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 9/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354010 | 0.91 | ALDH1A1 (0.65) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL20344330 | 0.86 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL24426732 | 0.84 | ALDH1A1 (0.73) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL3917747 | 0.83 | ALDH1A1 (0.78) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL29403771 | 0.82 | ALDH1A1 (0.69) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL29403396 | 0.81 | ALDH1A1 (0.76) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL20353929 | 0.80 | ALDH1A1 (0.70) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL20340699 | 0.80 | ALDH1A1 (0.70) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL24426910 | 0.80 | ALDH1A1 (0.58) | ALDH1A1RAB9AMAPTHTTPOLB | |
| SCHEMBL20353834 | 0.78 | ALDH1A1 (0.68) | ALDH1A1RAB9AMAPTHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807618-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2023-11-07 | — | — | US | disclosed |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2023-11-07 | — | — | US | disclosed |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2023-11-07 | — | — | US | disclosed |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-07-07 | — | — | US | disclosed |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-07-07 | — | — | US | disclosed |
| EP-3562818-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-05-18 | — | — | EP | disclosed |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2022-03-22 | — | — | US | disclosed |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2022-03-22 | — | — | US | disclosed |
| US-20190352275-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2019-11-21 | — | — | US | disclosed |
| US-20190352275-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2019-11-21 | — | — | US | disclosed |
| EP-3562818-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | Enyo Pharma (FR) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122317-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122317-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | ALDH1A1 3437/4885RAB9A 1661/4885MAPT 3934/4885 |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | ALDH1A1 1759/4885RAB9A 1653/4885MAPT 4150/4885 |
| US-20190352275-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | ALDH1A1 1759/4885RAB9A 1653/4885MAPT 4150/4885 |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | ALDH1A1 3437/4885RAB9A 1661/4885MAPT 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.